loader2
Partner With Us NRI

Company details

430.15
442.55
376.00
761.95
6M Return -19.59%
1Y Return -41.54%
Mkt Cap.(Cr) 5,357.49
Volume 9,758
Div Yield 4.80%
OI
-
OI Chg %
-
Volume 9,758

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Rapid Results

Q1FY23 Quarterly Result Announced for Glenmark Life Sciences Ltd.

Glenmark Life Sciences announced Q1FY23 results:

  • GLS registered revenue from operations of Rs 4,898.7 million for Q1 FY23, recording a YoY decline of 6.7% due to high base of COVID products sales last year. ( 6.5% YoY excluding COVID products)
  • Gross margins for the quarter improved to 53.3% mainly driven by booking of PLI scheme incentive. Gross Margins excluding PLI scheme incentive were stable at 52.0 % driven by better product mix and cost optimization efforts.
  • Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) was at Rs 1,562.6 million for Q1 FY23 with margin at 31.9%.
  • Profit After Tax (PAT) was at Rs 1,087.3 million in Q1 FY23, registering a growth of 7.7% YoY

Commenting on the company’s performance, Dr. Yasir Rawjee, MD & CEO, Glenmark Life Sciences Limited said, “We are pleased with our performance in this quarter with the overall business growing steadily, ex-covid products. India, LATAM, and ROW continue to lead our growth with Europe being soft due to supply chain issues. Generic API business saw a healthy growth of 7.1% YoY ex-covid products, whereas CDMO business witnessed an impact due to inventory rationalisation at customers’ end. We are witnessing improvement in demand for APIs across geographies, and I am optimistic about continuing the growth momentum in coming quarters”

Dr. Rawjee further added, “Our CAPEX plans are slightly delayed but we expect closure on some of these investments by the end of Q2 FY23. Our brownfield projects continue to be on track and will be completed by the end of this fiscal year. The addition of these new capacities will facilitate sustainable growth as we expand our product portfolio and continue to deliver higher volumes for existing products in the coming years.”

 

Result PDF

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 752.75 Cr FV: 2.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 1,063.73 35,237.03
LAST 3M 39,397.70 -2,125.67
LAST 6M 127,269.18 -146,884.65
LAST 12M 212,893.82 -215,286.28

Information

  • About Company
  • Company Info
  • Listing Info
12.56
82.85%
167.662
96.75%
60.91%
Description
  • The company was incorporated as `Zorg Laboratories Private Limited`, a private limited company under the Companies Act, 1956 on 23 June 2011 at Pune and was granted the certificate of incorporation by the Registrar of Companies, Maharashtra at Pune ("RoC"). Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to `Glenmark Life Sciences Private Limited` pursuant to a special resolution passed by the shareholders of the Company on 25 July 2018 and a fresh certificate of incorporation dated 10 August 2018 was issued by the RoC. A shareholders` resolution was passed on 13 August 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited. The Company acquired API division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January 2019. The company is primarily engaged in the business of development,manufacture and marketing of Active Pharmaceutical Ingredients(APIs). The company`s R&D facilities are located at Mahape,Ankleshwar and Dahej and manufacturing facilities are located at Ankleshwar,Dahej,Mohol and Kurkumbh. During the year 2018-19, the company allotted 4,50,090 Equity Shares of Rs. 10/- each on the conversion of loan given to Director. During the year, 15,00,000 equity shares of the face value of Rs. 10 each fully paid-up issued to Glenmark Pharmaceuticals Limited (Parent Company) pursuant to the Preferential Allotment. Subsequent to the quarter ended 30 June 2021, the company has completed the IPO of 21,022,222 equity shares comprising a fresh issue of 14,722,222 equity shares and offer for sale of 6,300,000 equity shares of face value of Rs 2 each at premium of Rs 718 per share aggregating to Rs 15,136 million. Pursuant to the IPO, the equity shares of the Company are listed on BSE Limited and National Stock Exchange of India Limited with effect from 06 August 2021. The Gross Debt comprising of Outstanding Purchase Consideration payable to the Parent Company was Rs 8,008.3 million as on 09 July 2021.The Company has repaid the whole of this remaining outstanding purchase consideration from the proceeds of the Fresh Issue pursuant to the IPO.

Read More

Registered Address

Plot No. 170-172 Chandramouli, Industrial Est.Mohol Bazarpeth, Solapur, Maharashtra, 413213

Tel : 91-2189-234456/234246
Email : complianceofficer:glenmarklifesciences.com
Website : http://www.glenmarklifesciences.com

Registrar

KFin Techologies Ltd

AGM Date (Month) :
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 543322
NSE Code : GLS
Book Closure Date (Month) :
BSE Group : B
ISIN : INE03Q201024

ICICIdirect Glenmark Life Sciences Ltd FAQ

You can buy Glenmark Life Sciences Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Glenmark Life Sciences Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Aug 12, 2022 04:01 PM the closing price of Glenmark Life Sciences Ltd was ₹ 437.25.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Aug 12, 2022 04:01 PM, the market cap of Glenmark Life Sciences Ltd stood at ₹ 5,357.49.
The latest PE ratio of Glenmark Life Sciences Ltd as of Aug 12, 2022 04:01 PM is 12.56
The latest PB ratio of Glenmark Life Sciences Ltd as of Aug 12, 2022 04:01 PM is 0.38
The 52-week high of Glenmark Life Sciences Ltd is ₹ 761.95 while the 52-week low is ₹ 376.00 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE